Geneseq Biosciences is a precision medicine company, based in Melbourne, Australia.

We specialise in developing novel genomic tests that help healthcare professionals diagnose cancer early and accurately.

Our first test, Melaseq™, detects the genomic fingerprint of malignant melanoma in blood or skin biopsy tissue.


The Challenge:

Melanoma develops from pigmented skin cells and if left undiagnosed, can spread to distant organs.
    • Melanoma, the deadliest form of skin cancer, is known as ‘Australia’s National Cancer’ and kills 5 people per day – more than the road toll.
    • Melanoma is the leading cause of cancer death in people aged 20-39yrs.
    • Current methods of diagnosing melanoma are subjective, resulting in 1 out of 6 melanomas being misdiagnosed.
    • Unlike other common cancers, the mortality rate of melanoma is increasing – and is 33% more deadly now than it was in the 1980s
    • Over $1 billion is spent on skin cancer procedures and treatment every year in Australia, more than any other cancer type – yet death rates continue to increase.

(Part Of) The Solution:

Geneseq Biosciences have identified a genetic fingerprint of malignant melanoma that can be measured using a standard blood test – or from excised skin biopsy tissue. Continue reading “Melaseq™”


Melaseq development and validation studies have been published in leading peer-reviewed medical journals, including the British Journal of Cancer, Plos ONE and Melanoma Research.



Publication abstracts, press excerpts and conference presentations can be viewed below.

Continue reading “Publications”

Our Progress

We began developing Melaseq, the worlds first non-invasive cancer biomarker in 2016, after years of research in cancer genomics and assay development.

Click to view an annotated timeline of our Melaseq development progress and company milestones.

Continue reading “Our Progress”

About Us

Geneseq Biosciences was founded by Ryan Van Laar Ph.D., a translational genomics scientist with over 20 years of experience in designing, validating and clinically performing cancer tests.

Geneseq Founder Dr. Van Laar Ph.D.

Dr Van Laar has over 25 peer-reviewed publications, international patents, and has been involved in multiple FDA approvals of novel & proprietary genomic assays.

Before founding Geneseq Biosciences, he was Vice President of Research & Operations and Laboratory Director for Signal Genetics, based in New York, NY and Little Rock, AR, USA.

Australian Clinical Labs.

In 2018, Australian Clinical Labs and Geneseq Biosciences formed a partnership to bring the first non-invasive melanoma test to market under the trademark Melaseq™.

Clinical Labs is the largest pathology provider to public hospitals in Australia and one of the top choices amongst private practices across the country. With over 90 NATA accredited laboratories and 900 collection sites nation-wide, the company performs around 8 million episodes a year for a range of clients including doctors, specialists, patients, hospitals and corporate clients.

Clinical Labs is a leader in molecular testing and new technologies and employs over 3,800 employees including more than 90 highly respected and experienced pathologists.

Continue reading “About Us”